Valuation: Incyte Corporation

Market Cap 23.37B 20.77B 19.38B 17.67B 33.32B 2,247B 33.63B 235B 90.89B 1,149B 87.75B 85.84B 3,686B P/E 2026 *
54x
P/E 2027 * 15.9x
Enterprise Value 19.1B 16.97B 15.84B 14.43B 27.22B 1,836B 27.47B 192B 74.26B 938B 71.69B 70.14B 3,012B EV / Sales 2026 *
3.21x
EV / Sales 2027 * 2.78x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day-2.54%
1 week-5.47%
Current month-3.85%
1 month-3.04%
3 months+4.18%
6 months+28.98%
Current year+23.45%
1 week 103.6
Extreme 103.6
109.1
1 month 103.6
Extreme 103.6
111.5
Current year 77.6
Extreme 77.6
115.4
1 year 72.28
Extreme 72.28
115.4
3 years 47.11
Extreme 47.11
115.4
5 years 47.11
Extreme 47.11
115.4
10 years 47.11
Extreme 47.11
144.13
Manager TitleAgeSince
Chief Executive Officer 58 25/06/2025
Director of Finance/CFO 57 03/05/2026
President 62 04/06/2023
Director TitleAgeSince
Chairman 59 25/06/2025
Director/Board Member 72 19/01/2015
Director/Board Member 64 19/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
-2.54%-5.47% - - 23.37B
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average -0.47%-3.39%+27.17%+57.15% 410.8B
Weighted average by Cap. +0.40%-3.33%+30.52%+68.96%

Financials

2026 *2027 *
Net sales 5.94B 5.28B 4.93B 4.49B 8.47B 571B 8.55B 59.61B 23.1B 292B 22.3B 21.82B 937B 6.26B 5.56B 5.19B 4.73B 8.92B 602B 9B 62.81B 24.34B 308B 23.5B 22.99B 987B
Net income 445M 395M 369M 336M 634M 42.77B 640M 4.46B 1.73B 21.86B 1.67B 1.63B 70.16B 1.5B 1.34B 1.25B 1.14B 2.14B 145B 2.16B 15.09B 5.85B 73.91B 5.65B 5.52B 237B
Net Debt -4.28B -3.8B -3.55B -3.23B -6.09B -411B -6.15B -42.91B -16.63B -210B -16.05B -15.7B -674B -5.96B -5.3B -4.94B -4.51B -8.5B -573B -8.58B -59.82B -23.18B -293B -22.38B -21.89B -940B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
02/10/26 €103.60 -2.54% 0
01/10/26 €106.30 -1.35% 145
30/09/26 €107.75 -0.83% 0
29/09/26 €108.65 -0.41% 0
28/09/26 €109.10 -0.46% 90
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
115.30USD
Average target price
128.42USD
Spread / Average Target
+11.38%

Quarterly revenue - Rate of surprise